Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer

Phase I/II Study of Dose-Escalated Hypofractionated Radiotherapy for Low- and Intermediate-Risk Prostate Cancer

The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (40 Gy / 5 fractions / 29 days) for the treatment of low- and intermediate-risk prostate cancer.

Inclusion Criteria:

• Men >18 years
• Histologically confirmed prostate adenocarcinoma
• Low or low-intermediate risk prostate cancer, defined as Clinical stage T1-2b, Gleason Score <=6, and PSA <15 ng/mL, OR Clinical stage T1-2b, Gleason Score 7, and PSA <=10 ng/mL

Exclusion Criteria:

• Prior pelvic radiotherapy
• Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
• Diagnosis of bleeding diathesis
• Presence of a hip prosthesis
• Pelvic girth >40cm - Large prostate (>90cm3) on imaging
• Severe lower urinary tract symptoms (International Prostate Symptom Score >19 or nocturia >3)